- The company’s revenues are growing at 40% while the share price is lingering.
- The revenue growth has also brought a remarkable margin expansion in both gross and operating margins.
- Cash outflows have been reduced significantly as a result and are likely to diminish further.
Improvements At Neos Therapeutics Aren’t Reflected In The Share Price
December 30th, 2019 · No Comments